title: Captopril renal scintigraphy in patients with hypertension and chronic renal failure.
abstract: The aim of this prospective study was to determine the ability of the captopril renogram to reveal the presence of angiotensin II-dependent renovascular disorder in hypertensive patients with chronic renal failure and to assess the possibility of predicting beneficial effect of angiotensin-converting enzyme (ACE) inhibitors on renal function.
  
  
  METHODS
  Forty-one patients were evaluated. Baseline renal scintigraphy was performed with 80 MBq of 99mTc-mercaptoacetyltriglycine (MAG3) injected intravenously. Scintigraphy was repeated within a week with 25 mg of oral captopril given 60 min prior to the test. Using the measurements outlined by the Working Party on Diagnostic Criteria of Renovascular Hypertension with Captopril Renography, the patients were categorized into high (7 patients), indeterminate (19 patients) and low (15 patients) probability for renal artery stenosis (RAS).
  
  
  RESULTS
  In five of the seven patients with high probability, the presence of RAS was confirmed angiographically and corrective surgical procedure performed in two. In patients with GFR of 10 ml/min/1.73 m2 and/or split renal function of 10% or less, all qualitative and semiquantitative scintigraphic parameters were nonspecific. Mean parenchymal transit time of tracer was a useful parameter to predict the beneficial effect of ACE inhibition therapy in 23 patients (14 low and 9 indeterminate probability of RAS).
  
  
  CONCLUSIONS
  In hypertensive patients with renal failure, captopril renal scintigraphy can be utilized to identify the presence of angiotensin II-dependent renal dysfunction and possibly help to predict the beneficial effect of ACE inhibitor therapy.
authors.affiliation: Department of Nuclear Medicine, St. Bartholomew's Hospital, London, England, UK.
authors.forename: I E
authors.initials: IE
authors.lastname: Datseris
authors.forename: J B
authors.initials: JB
authors.lastname: Bomanji
authors.forename: E A
authors.initials: EA
authors.lastname: Brown
authors.forename: K S
authors.initials: KS
authors.lastname: Nijran
authors.forename: A K
authors.initials: AK
authors.lastname: Padhy
authors.forename: Q H
authors.initials: QH
authors.lastname: Siraj
authors.forename: K E
authors.initials: KE
authors.lastname: Britton
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D002216:Captopril; D005260:Female; D006801:Humans; D006978:Hypertension, Renovascular / Q000150:complications / Q000000981:diagnostic imaging*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011877:Radionuclide Imaging; D017263:Technetium Tc 99m Mertiatide
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D017263:Technetium Tc 99m Mertiatide; D002216:Captopril